# Effectiveness of Dupilumab in Food Allergic Patients With Moderate to Severe Atopic Dermatitis

> **NCT04462055** · — · TERMINATED · sponsor: **UMC Utrecht** · enrollment: 3 (actual)

## Conditions studied

- Food Allergy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04462055
- **Lead sponsor:** UMC Utrecht
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Not feasible to include patients (due to e.g. COVID-19, patients with severe reactions not willing to undergo 2 food challenges, lower number of eligible patients than expected)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04462055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04462055, "Effectiveness of Dupilumab in Food Allergic Patients With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04462055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*